Volume 94 Issue 7 | p. 8 | News of The Week
Issue Date: February 15, 2016 | Web Date: February 10, 2016

Yumanity Therapeutics Reaps $45 Million In Financing

Start-ups: Investors respond strongly to firm’s novel approach to neurodegenerative diseases
Department: Business
News Channels: Biological SCENE
Keywords: discovery, neuroscience, venture capital, Alzheimer’s, Parkinson’s, ALS

Yumanity Therapeutics, a neuroscience start-up launched in 2014 by high-profile founders, has raised $45 million in its first funding round. The investment endorses the company’s novel approach to tackling Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis—diseases that are frustrating drug development at some of the world’s largest pharma firms.

The large influx of capital is an unusually “big raise” for a company still early in the discovery process, admits CEO Tony Coles, . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society